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Zusammenfassung
Effects of Patient Motion on Absolute Quantification
in Cardiac Positron Emission Tomography (PET)
Jo¨rg Eckardt
Die Positronen-Emissions-Tomographie (PET) stellt eine der leistungs-
fa¨higsten Methoden zur Bestimmung myokardialer Vitalita¨t dar, deren Be-
stimmung fu¨r die Prognose und Therapie von Patienten mit koronarer Herz-
erkrankung elementar ist.
Ziel der vorliegenden Arbeit war es, das Auftreten und die Einflu¨sse von
Patientenbewegung anhand von klinischen und simulierten Daten zu unter-
suchen. Ein numerisches Herzmodell wurde neu entwickelt, die Einflu¨sse von
ku¨nstlichen Bewegungen auf das Modell und klinische Daten untersucht und
diese Ergebnisse mit bewegungskontaminierten klinischen Daten verglichen.
Es wurde festgestellt, dass Patientenbewegung in mehr als einem Drit-
tel der PET-Untersuchungen auftritt. Die simulierten Bewegungsartefakte
zeigten gleiche Ergebnisse fu¨r das Modell und die klinischen Daten. Der
Vergleich mit klinischen Bewegungsartefakten besta¨tigt diese Ergebnisse.
Tag der mu¨ndlichen Pru¨fung: 25.09 und 01.10.2003
CONTENTS 4
Contents
1 Introduction 9
2 Basics 11
2.1 Detection of Myocardial Viability . . . . . . . . . . . . . . . . 11
2.2 Positron Emission Tomography . . . . . . . . . . . . . . . . . 13
3 Aim 30
4 Material and Methods 31
4.1 Registration and Correction of Patient Motion . . . . . . . . 31
4.2 Software Phantom . . . . . . . . . . . . . . . . . . . . . . . . 32
4.3 Patient Data . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.4 Simulation of Motion . . . . . . . . . . . . . . . . . . . . . . . 37
4.5 PET-Scanner and Image Reconstruction . . . . . . . . . . . . 39
4.6 Quantitative Analysis of Glucose Metabolism . . . . . . . . . 40
4.7 Software Issues . . . . . . . . . . . . . . . . . . . . . . . . . . 41
5 Results 42
5.1 Clinical Relevance: Registration of Patient Motion . . . . . . . 42
5.2 Validation I: Simulation vs. Artificial Motion . . . . . . . . . . 42
5.3 Validation II: Simulation vs. Clinical Motion . . . . . . . . . . 48
6 Discussion 49
6.1 Clinical Relevance: Motion Detection . . . . . . . . . . . . . . 49
CONTENTS 5
6.2 Validation I: Simulation vs. Artificial Motion . . . . . . . . . . 50
6.3 Validation II: Simulation vs. Clinical Motion . . . . . . . . . . 54
6.4 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
7 Conclusion 57
8 Curriculum Vitae 58
9 Acknowledgements 60
LIST OF FIGURES 6
List of Figures
1 Principle of β+-decay: formation of the positron (β+-radiation)
and annihilation process resulting in γ-radiation [55]. (P: proton,
N: neutron, e+: positron, e−: electron, ν: neutrino) . . . . . . . . 13
2 Principles of a cyclotron . . . . . . . . . . . . . . . . . . . . . . 18
3 Structure responsible for different biochemical pathways (chapter
2.2.4): 2-Fluoro(18)-2-Deoxy-D-Glucose (right) differs from D-Glu-
cose (left) only in the replacement of the hydroxyl group on the
second carbon atom. . . . . . . . . . . . . . . . . . . . . . . . . 20
4 Coincidence detection in a PET-scanner [55] . . . . . . . . . . . . 22
5 Three-compartment model of the metabolic process of 2-Fluoro(18)-
2-Deoxy-D-Glucose. . . . . . . . . . . . . . . . . . . . . . . . . 24
6 Patlak Plot . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
7 Geometrical shape of the heart phantom developed according to
anatomical findings; the myocardium is hatched, all units are given
in mm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
8 Anatomy of the heart and definition of the x’- and y’-axis [55]. 33
9 Segmentation of the LV and its x’ and y’ axis definition. . . . . . 34
10 Visualisation of correlation between translation and rotation. The
centre of rotation is P in the scanner coordinate-system, ~s the
translational part of movement and the rotation angle φ. The
rotation is visualised by the dotted line. . . . . . . . . . . . . . . 37
LIST OF FIGURES 7
11 Definition of the x-, y-, and z-axis . . . . . . . . . . . . . . . . 39
12 Operation of the registration algorithm: the regions depicted in
both images are located identically. . . . . . . . . . . . . . . . . 43
13 Results of the registration algorithm . . . . . . . . . . . . . . . 44
14 Effects of translation on Patlak-plot for a translation of 8 pixels
in x-direction, region Inf-B: left before frame 30 (20.5 min.), right
before frame 37 (40.5 min) . . . . . . . . . . . . . . . . . . . . . 45
15 Effects of myocardial thickness on the line profiles of the myocar-
dial wall (left). Comparison of the marked line profile of a thick
myocardium (patient 1) with a thin myocardium (patient 2) and 2
phantoms representing different myocardial thicknesses and back-
ground levels. Colorbar values are relative. . . . . . . . . . . . . 46
16 Effects of translation: x- (1. row), y- (2. row), and z-direction
(3. row), all translations noted with their absolute value in the
positive direction: left patient data, right phantom data . . . . . . 47
17 Effects of rotations around different axis: x’- and y’- (average left),
and z-direction (right), all rotations noted with their absolute value
in the positive direction: left patient data, right phantom data . . 48
18 Effects of motion correction on classification of myocardial regions:
ratio of corrected vs uncorrected patient data (PCM group) com-
pared to artificial shifted patient (PAM group) and phantom data. 49
LIST OF TABLES 8
List of Tables
1 Properties of commonly used radio-isotopes [3, 7, 6] . . . . . . 16
2 Heart VOIs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3 Time schedule of a clinical FDG scan. (Injection in frame 2) . . . 35
4 Classification of the relative glucose consumption measured with
FDG-PET in clinically relevant groups [35]. Values are presented
as relative numbers in relation to the region with the maximum
glucose metabolism. . . . . . . . . . . . . . . . . . . . . . . . . 41
1 INTRODUCTION 9
1 Introduction
Coronary artery disease is the leading cause for mortality in the developed
countries. Advances in pharmacological, interventionell, and surgical ther-
apy (e.g. coronary revascularization and heart transplantation) help to re-
duce mortality in those patients. Correct assessment of the extent of viable
and non viable myocardium is one key figure for clinical decision making.
Detection of viability based on the assessment of glucose metabolism with
Positron Emission Tomography (PET) is a clinical reference method [64],
other methods as contrast-enhanced Magnetic Resonance Imaging [30] or
echocardiography [67] are also validated approaches.
The strength of PET with 18F-FDG in this field is its ability to quantify
glucose metabolism in absolute numbers three dimensionally [47] whereby
scanning procedures of more than 1 h are necessary [32]. Effects of patient
motion during imaging procedures with long scanning times like SPECT
are well known [19, 14]. Although motion in PET can be determined and
corrected within some limits [28, 56, 53], patient data is rarely corrected for
motion. Effects of motion-biased data on absolute quantification is assumed
[34, 27] rather than investigated.
The aim of this work is the determination of patient movement which
occurs unsystematically and often unrecognizable by the investigator in clin-
ical practice. Furthermore effects of patient motion on the calculation of
glucose metabolism will be analyzed. Effects on the results of absolute glu-
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cose metabolism will be studied on phantom data and in a clinical setup
on artificially motion-biased data. The impact of this results on the clinical
work will be investigated by application of these results on patient data with
and without movement correction methods.
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2 Basics
2.1 Detection of Myocardial Viability
Myocardial viability is a key parameter in the selection of patients for my-
ocardial revascularization procedures. Since electrocardiographic methods
are usually not sufficient for this detection imaging procedures have to be
carried out [40]. The next section will describe briefly different imaging
methods for the detection of myocardial viability with their advantages and
disadvantages [50].
2.1.1 Ultrasound Imaging
Dobutamine Stress Echocardiography (DSE) investigates the difference in
contractility between a rest situation and pharmacologically evoked stimula-
tion of the heart by ultrasound. It detects the contractile reserve of the heart
which correlates to its physiological status [54]. Best results are provided
when detecting a “biphasic response”: at low pharmacological concentrations
of the stress agent an improvement of contractility is detected whereas at
high concentrations a hypokinesis of the investigated wall segment is evoked
due to a lack of oxygen provoked by coronary stenosis [11].
Myocardial Contrast Echocardiography (MCE) uses contrast media com-
posed of a solution of microbubbles or occasionally air filled microspheres for
blood pool marking. Assuming, that myocardial viability necessitates a pre-
served microcirculation and implying a preserved microvasculature MCE is
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capable of detecing myocardial perfusion. Segmental wall motion and hence
myocardial viability is verified on a high level [67].
2.1.2 Magnetic Resonance Imaging
Stress Magnetic Resonance Imaging (SMRI) uses the same pharmacolog-
ical approach as DSE. Due to the superior spatial resolution and a three-
dimensional approach quantitative determination of contractility is possible.
Nevertheless, reported specifity and sensitivity show discrepancies [11], par-
tially explainable by different criteria. SMRI provides results for detection of
myocardial viability, comparable to other methods described here. Contrast
enhancement with Gd-DTPA shows promising results [46].
Magnetic Resonance Spectroscopy (MRS) is capable of accessing the
chemical composition of tissue. This method is technically complex and still
under development, although first results are quite promising [11]. Spatial
resolution cannot compete with SMRI.
2.1.3 Positron Emission Tomography
PET in relation to the other imaging techniques is still known for the highest
sensitivity in the detection of myocardial viability whereas the specifity is
inferior to other methods [37, 11]. Its ability to obtain absolute values of
metabolic rates is unique.
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2.2 Positron Emission Tomography
Postiron Emission Tomography is a technique which is able to detect the
distribution of positron-emitters three-dimensionally. In this chapter physical
properties of positron decay, production of positron emitters, radioactive
labelling of pharmaceuticals and analysis of PET-data will be described.
2.2.1 Positron Decay
N e+
e−
ν
N
N P
PP
P
P
N
NP
N
N
N P
PP
P
P
N
NN
unstable parent
nucleus
positron decays to neutron 
in nucleus, positron and 
neutrino emitted
positron combines with
electron and annihilates
γ
γ
two anti− parallel 511 keV
photons produced
Figure 1: Principle of β+-decay: formation of the positron (β+-radiation) and
annihilation process resulting in γ-radiation [55]. (P: proton, N: neutron, e+:
positron, e−: electron, ν: neutrino)
Positron decay is one of the three beta decay processes. These are char-
acterized by the transition of the charge of a nucleon. A positron or an
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electron and its corresponding neutrino is generated in the nucleus. Hereby
the atomic number is modified by one unit, the chemical element changes,
and the mass number A is constant. In the case of the β+-decay, the atomic
number decreases by one, and the positron, describable as a positive charged
electron is emitted:
A
ZX −→
A
Z−1 YN+1 + e
+ + νe. (1)
The particle νe on the right hand side of (1) is the electronic neutrino;
since it is only measurable with modern and sophisticated equipment it was
initially undetectable but postulated. It has no direct effect on any part of
the PET-equipment; only its involvement in the decay reaction results in a
statistical distribution of the reaction energy over the three emitted particles.
With no neutrino involved the energy would be distributed to the nucleus
and the positron exactly with respect to their masses.
As visualized in figure 1 the emitted positrons are slowed down by in-
teractions with the electrons in matter. Positrons are counted among anti-
matter; if the energy degradation is sufficient, the positron reacts with its
anti-particle, the electron, leading to an annihilation process [31].
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2.2.2 Production of Radiopharmaceuticals with a Cyclotron
Physical and Biochemical Characteristics of Radiopharmaceuticals
A radiopharmaceutical is a pharmaceutical with a radioactive entity. It may
be seen from two points of view affecting each other: the physical one, dealing
with the nuclear characteristics of the emitting atom and on the other hand
the biochemical one, taking the chemical characteristics, the behavior in a
human organism with all its metabolic processes into account.
From the physical point of view the limitations affect the choice of the
radiating atom in the chemical bond:
• type of emitted radiation: since absorption for pure α- and β−-radiation
in tissue is high, γ-emitting nuclides are used for Single Photon Emission
Computed Tomography (SPECT) and PET.
• energy of emitted radiation: absorption for γ-emitting nuclides in tissue
is strongly depending on their energy; suitable for imaging purposes are
only those with an energy between 70 keV and 511 keV.
• half-life of the radiopharmaceutical: it must be long enough to make
the imaging process possible resulting in a minimum half-life of about
60 s. From the radiation protection point of view, the half-life must
be as short as possible, limiting the half-life of the usable nuclides for
human diagnostic purposes to a few hours.
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Positron-emitting radionuclides can be produced with a cyclotron or via a
generator-system. The choice is not totally free and depends mostly on the
individual nuclide desired.
From the biochemical point of view, the limitations result from the desire
to visualize the metabolic process of the radiopharmaceutical similar or equal
to a physiological one, or at least characteristic for it:
• good uptake in tissue
• no metabolic processes except from the desired ones
Although many radiation-emitting nuclides are known, the number of
usable ones is quite limited with respect to physical and biochemical issues.
Both points of view are mostly addressed by labelling pharmaceuticals with
positron emitters produced with a cyclotron. Hence it will be described in
the next chapter.
Isotope half-life Maximum Mean positron Production
positron energy range in water method
[min] [MeV] [FWHM im mm]
11C 20.3 0.96 0.85 cyclotron
13N 9.97 1.19 1.15 cyclotron
15O 2.03 1.72 1.8 cyclotron
18F 109.8 0.64 0.46 cyclotron
68Ga 67.8 1.90 2.15 generator
82Rb 1.26 3.35 4.1 generator
Table 1: Properties of commonly used radio-isotopes [3, 7, 6]
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Production of Positron Emitters with a Cyclotron
Since the half-life of the presented positron emitters is short, they are not
found in nature. Positron emitters are characterized by being rich in pro-
tons; therefore the aim of any production method is the enrichment of pos-
itive charge in a nucleus. The only direct access is the transport of protons
(positively charged) into the nucleus. The Coulomb-force repels the similarly
charged proton and the nucleus from each other. This long-range repulsive
force must be overcome to bring the protons in the (low-range) reach of the
nuclear force which keeps the proton inside the nucleus. Hence the proton
must be accelerated to high velocities (mostly expressed in units of energy,
ranging in a few MeV) which is possible with different particle accelerators
[38]. Mostly, cyclotrons are used for the production of high energy protons,
hence its function will be described briefly.
The acceleration of particles on a non-linear spiral way was invented in
1932 [33], its principle delineated in figure 2. It consists of an ion source
placed in the middle of the 4 dees (electrodes) all situated in a high-vacuum.
Each dee consists of two (one upon the other) electrically connected plates
where adjacent dees are also electrically connected (same color in figure 2).
A large electric coil is depicted only by the resulting magnetic field.
A negatively charged hydrogene-ion (proton with 2 electrons) is emitted
radially from the negatively charged ion source. Entering the region of the
dees it is repelled from the negatively charged dee in counter-clockwise di-
rection (depicted black) and attracted from the positively charged (depicted
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Figure 2: Principles of a cyclotron
grey) in clockwise direction. In the moment the ion passes through the two
plates of the dee in the clockwise direction (depicted grey) the polarity of
the dees is changed. After passing the ion is again repelled from the now
negatively charged dee in counter-clockwise direction and attracted from the
positively charged in clockwise direction The spiral pathway in this process is
caused by the magnetic field: the Lorentz-Force effects perpendicular to the
direction of movement of the charge particle and the magnetic flux lines, in
direction of the centre of the spiral. Since it is not large enough to compen-
sate the centrifugal force fully the radius of the ion’s pathway increases. By
high frequent change of the electric polarity of the dees the ion is accelerated
further on. When the ion passes the stripping foil, the 2 electrons are pulled
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of the ion and a proton remains, travelling further on. Thereby the Lorenz-
Force effects in the radial direction driving the proton out of the acceleration
field into the target. Target reactions depend on the energy of the incident
proton and the target filling-material. One possible reaction is
18O + p −→18 F + n. (2)
A full description with the exact physical derivation can be found in [59]
the coverage of substantially questions of radiation protection in this field in
[15, 24].
Radioactive Labelling of Pharmaceuticals
Once a radioactive nuclide is produced, a pharmaceutical is to be labelled
with it. Since PET-radiochemistry is a complex field only the key demands
should be addressed here shortly, an introduction can be found in [49, 58].
• A basic need is a fast labelling process in units of the half-life of the
radioactive nuclide used. The layout of the synthesis is chosen best,
when the radioactive labelling is conducted late in the synthesis.
• Many applications like imaging neurotransmitters or enzymes require
radiotracers with high specific activities. Though chemistry with small-
est amounts of substances (nanomolar quantities) requires sophisticated
planning of reactions
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• Due to the short half-life, quality control of the radiopharmaceutical
cannot be performed for all currently accepted ones before application.
Basic tests are conducted before, quality control is performed according
to legal regulation additionally including control of starting materials,
stability tests, tests after application (e. g. for sterility and apyrogen-
ity).
• The activities handled are high (range of GBq) implying a high radia-
tion level. To address radiation protection issues radiochemistry must
be widely remotely controlled and performed in lead-shielded gas-tight
hot-cells.
The mostly used PET-tracer also used in this thesis is 2-Fluoro(18)-2-Deoxy-
D-Glucose (FDG) as shown in figure 3 and its clinical role is extensively
investigated [22].
O
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H F18
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OH
D−Glucose 2−[18F]−Fluor−2−desoxy−D−glucose (FDG)
Figure 3: Structure responsible for different biochemical pathways (chapter 2.2.4):
2-Fluoro(18)-2-Deoxy-D-Glucose (right) differs from D-Glucose (left) only in the
replacement of the hydroxyl group on the second carbon atom.
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2.2.3 Positron Emission Tomograph
The key issue in scintigraphic imaging is not only to detect an ionizing par-
ticle but also to receive information about its origin. A Positron Emission
Tomograph is principally designed as shown in figure 4. Many small scintil-
lators (approx. 10000) are placed on a ring around the field of view. Each
detector element is optically connected with an electronic device able to de-
tect the γ-quants emitted at the annihilation process of a positron. Since
the time of travelling is short it can be assumed, that two γ-quants, detected
in a short time-window (in the range of 10 ns), belong to the same annihi-
lation process. The origin of emission and hence the place of annihilation
lies somewhere on the direct line between these two detectors (LOR= Line
Of Response). The so-called coincidence detection is visualized in figure 4:
only events detected in both channels are assumed to originate frome one
annihilation process and are selected for the imaging process.
PET-data is biased by different effects which are corrected for:
• Attenuation in the tissue: this effect is corrected by a transmission scan
provided by rotating radioactive sources [65, 61] or alternatively by a
CT system [29].
• Random coincidences, caused by two γ-quants emitted by different an-
nihilation incidences and being accidently identified as being coincident
[9].
• Scatter is evoked by one of the 2 coincident detected γ-quants being
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Channel 1
Channel 2
Channel
coincidence events
Summed
γ
γ
Annihilation event
Figure 4: Coincidence detection in a PET-scanner [55]
scattered in tissue and resulting in a false LOR [66, 2].
• Dead time occurs since the detectors have a limited count rate capabil-
ity; γ-quants irradiating one detection element in high frequency (scale
of ms−1) cannot be differentiated by this detection element [8].
• Different sensitivities of different LORs are evoked by different sensi-
tivity of the detection elements themselves and geometric reasons [43].
After a mathematical reconstruction with respect to these corrections has
been carried out, the activity concentration in every point in the field of view
is obtainable with respect to the resolution of the system.
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2.2.4 Kinetic Model of 2-Fluoro(18)-2- Deoxy-Glucose (FDG)
The reconstructed data-set from the PET-scanner only gives information
about the physical three-dimensional distribution of the radioactive nuclide
injected to the patient. Combination of this physical data with information
about the metabolic pathway of the injected radiopharmaceutical is nescces-
sary. In this chapter the fundamentals of the FDG-model are delineated. De-
tails and their appliance to cardiac investigations can be found in [26, 47, 57].
Compartment Model
In the description of the compartmental model the difference between FDG
and D-glucose as depicted in figure 3 is important. The model used in this
work is a three-compartment model, the principle of which is visualized in
figure 5. All constants and variables concerning the radioactive FDG are
marked with an asterisk (e.g. k∗1, C
∗
p), those for the natural analogon without
(e.g. k1, Cp).
FDG is injected into a vein and thus distributed over the capillary system
of the whole body and reaches the myocardium. FDG in blood plasma is de-
fined as the first compartment. FDG is transported into the tissue by the
same transporter as glucose. The transport constant characterizing this pro-
cess for FDG is k∗1, for the reverse transport k
∗
2. Qualitatively, the metabolic
process for glucose and FDG is similar in the next step: FDG and glu-
cose are phosphorylized by the hexokinase reaction to FDG-6-phosphate and
glucose-6-phosphate respectively; the reaction is characterized for FDG with
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the constant k∗3, the backward reaction by k
∗
4. At this point the metabolic
pathway of glucose and FDG diverges: glucose-6-phosphate is isomerized to
fructose-6-phosphate and metabolized further the glycolytic and tricarboxylic
pathway. The isomerization of FDG is not possible due to the lack of the
hydroxyl group on its second carbon atom (figure 3). Hence FDG is trapped
in this compartment.
FDG in
tissue
FDG in
plasma
CE* CM*CP* k4*
k3*
k2*
k1* FDG−6−PO4
Figure 5: Three-compartment model of the metabolic process of 2-Fluoro(18)-2-
Deoxy-D-Glucose.
The model used makes the following assumptions:
• Glucose metabolism is in a steady state. The metabolic rate of glu-
cose and concentrations of all the substrates and intermediates of the
glycolytic pathway are constant during the time of the study
• Concentrations of glucose, FDG and FDG-6-P are small, are homoge-
nous in their compartments
• Concentrations of FDG and FDG-6-P are small relative to their natural
counterparts so that the presence of FDG and FDG-6-P does not affect
the steady-state environment of glucose metabolism.
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• The transport constants of FDG and FDG-6-P between compartments
have first-order kinetics.
• Tissue extraction fraction of glucose and FDG from plasma is small. In
other words, the transporters of glucose and FDG to local myocardial
tissue is not flow limited.
Using these assumptions an equation can be formulated which describes the
glucose consumption Ri in dependency of the transport constants of FDG
Ri =
1
LC
·
k∗1 · k
∗
3
k∗2 + k
∗
3
· Cp, (3)
whereby LC is the “Lumped Constant” representing a calibration factor
between the glucose and FDG transport. The concentration of glucose in
blood Cp is simply achievable from a single blood sample whereas the deriva-
tion of the transport constants is performed by means of a PET measurement.
Determination of Absolute Glucose Metabolism
Under these assumptions, a formula describing the dependency of the activ-
ity concentration C∗i in tissue from the plasma concentration C
∗
p(t) and the
transport constants k∗1-k
∗
4 can be written as [26]
C∗i (t) =
k∗1
α2 − α1
((k∗3 + k
∗
4 − α1) · e
−a1t +
2 BASICS 26
(α2 − k
∗
3 − k
∗
4) · e
−α2t) ⊗ C*p (t), (4)
with α1,2 =
k∗2 + k
∗
3 + k
∗
4 ∓
√
(k∗2 + k
∗
3 + k
∗
4)
2 − 4k∗2k
∗
4
2
.
How far k∗4 has to be taken into account is not treated on a standard way.
Some publication do this [26] others do not [57]. Here the formula for k∗4 6= 0
is presented.
Disregarding the back reaction of the phosphorylization reaction (k∗4 = 0)
formula 4 may be simplified to
C∗i (t) =
k∗1 · k
∗
3
k∗2 + k
∗
3
·
∫ t
0
C∗p(τ)dτ +
k∗1 · k
∗
3
k∗2 + k
∗
3
e−(k
∗
2
+k∗
3
)τ ·
∫ t
0
C∗p(τ) ·e
(k∗
2
+k∗
3
)τdτ (5)
The main task of FDG-PET in absolute quantification of glucose metabolism
is the determination of the transport constants k∗1-k
∗
4. Since activity con-
centration in tissue C∗i and in plasma C
∗
p is known a numerical solution of
equation 4 (iterative) and 5 can be found.
Patlak Plot
Looking at data obtained late in the acquisition process, the change of C∗p in
comparison to this of the exponential function can be disregarded. This can
be written as the linear equation [23, 44]
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C∗i (t)
C∗p(t)︸ ︷︷ ︸
=
k∗1 · k
∗
3
k∗2 + k
∗
3︸ ︷︷ ︸
·
∫ t
0
C∗p(τ)dτ
C∗p(t)︸ ︷︷ ︸
+
k∗1 · k
∗
2
(k∗2 + k
∗
3)
2︸ ︷︷ ︸
(6)
y = a · x + b
C∗p is obtainable from blood sample data, C
∗
i from the reconstructed ac-
quisition data. Plotting x and y with respect to the axis results in a straight
with the slope of a and a y-axis interception of b (figure 6). The slope of the
plot can be directly inserted into the equation (3).
0 50 100
Int CP*(τ) dτ/CP*(t)  /min
0
2
4
6
C i
*
(t)
 /C
P*
(t)
 
measured data
linear regression
k1
* 
 k3
*
k2
* 
+ k3
*
axis intercept:
(k2
* 
+ k3
*)2
slope:
k1
* 
 k2
*
Figure 6: Patlak Plot
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2.2.5 Motion
Influence of Motion and Misalignment
Motion in cardiac imaging can be divided in three types: motion due to
normal cardiac exercise of the heart, respiratory motion and patient motion at
a certain point of the investigation (e.g. related to uncomfortably positioning
of the patient). The first two types of motion may be treated with means of
cardiac or respiratory gating and are not investigated in this work.
The third type of motion (further on referred to as patient motion) is not
characterizable in a systematic way since it differs in its timing and dimension
from patient to patient and occurs randomly. It is known as a serious problem
in cardiac nuclear medicine investigations and has been described in the
literature. Results for 201Tl-SPECT were obtained on patient data [18, 17,
12, 19], phantom studies, simulated data [51, 16] or a combination of these
[5, 12]; an overview may be found in [19, 14]. 201Tl-SPECT-studies had
shown, that motion appears in 17 - 25 % of the cardiac 201Tl-investigations
[51, 5, 21, 20].
In contrast, data on motion effects in cardiac PET is rare: this might
be explained by the key difference of SPECT an PET acquisitions: perform-
ing multi-frame PET acquisition on a dedicated PET-scanner results in one
blurred frame which must not take effect on the diagnosis if only visual or
static semi-quantitative methods are used; contrarily SPECT acquisitions
will be affected wholly. Since the resolution of PET-acquisitions is higher
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and the acquisition time is longer, motion might be present more often.
Motion in between one acquisition frame results in different effects on the
reconstructed image, as loss of resolution and image artifacts in SPECT [19].
Conducting multi-frame acquisitions, inter-frame movement does not have
such serious effects on every single reconstructed frame except the one within
which the movement happened but might have serious effects on modelling
approaches.
Motion Detection and Correction
A basic need for overlay-techniques in inter-modality comparison of tomo-
graphic information is the right alignment of the 2 datasets which is compa-
rable with a motion estimation and correction algorithm. Image registration
is mostly applied in this field and has been widely evaluated and described.
General overviews of medical image registration can be found in [36] and [25]
the coverage in nuclear medicine in [28]. Also video-camera-based approaches
are published [48, 45].
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3 Aim
Aim of this thesis is the development of a dynamic software phantom for
evaluation of spatial influences on absolute quantification in cardiac PET.
This validity of the software phantom is validated on a special topic of spatial
influences, patient motion. This is conducted in 3 steps:
1. Clinical relevance: the relevance of the investigation is determined; the
occurrence of motion (patient data) in a clinical setup will be analyzed.
2. Validation I: movement will be simulated for phantom data. The results
will be validated with artificially moved patient data.
3. Validation II: the results of simulation will be further validated by
comparison with motion-corrected clinical data.
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4 Material and Methods
4.1 Registration and Correction of Patient Motion
Since few of the voxels of a given image contains relevant myocardial infor-
mation the motion registration process needs data preprocessing. A binary
coding of the image was performed (analogue to [60]) where every pixel over
a certain threshold was coded as 1 all others as 0.
Different methods for image registration are known and also tested in
nuclear imaging [42]. For the purposes of this work the simple but fast
method similar to the Sum of Absolute Differences (SAD)[60] was used:
almn =
1
N3
N∑
i=1
N∑
j=1
N∑
k=1
(xijk − yi+l, j+m k+n)
2
, (7)
where N is the side length of the cubic volume in pixels, almn is the
sum over the square of intensity differences of all pixels, the original one
(represented by xijk) and the shifted one (represented by yi+l, j+mk+n; l,m,n
shifts in x,- y-, z- direction respectively).
Since the Patlak Model is applicable to the later frames of the acquisition,
only those frames were investigated in the image registration process. The
correction method was applied on adjacent frame: the n-th (n ∈ [27; 36]n ∈
N) frame was compared with the n+1 th. The SAD-algorithm was stopped,
when a local minimum of almn was found. Registration was evaluated in steps
of whole pixels to avoid resampling artifacts. Results of the SAD algorithm
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were visually controlled.
The presented method registrates only translational movement. Motion
correction was performed by application of the results of the registration
process on the biased dataset using standard transformations.
4.2 Software Phantom
4.2.1 Geometry of the Software-Phantom
Figure 7: Geometrical shape of the heart phantom developed according to anatom-
ical findings; the myocardium is hatched, all units are given in mm
For the simulation of motion effects and motion correction a dynamic
software phantom has been developed. As shown in figure 7 the left ventri-
cle is simulated as a combination of a cylindrical and a spherical part and
matches reasonably the shape of the healthy left ventricle anatomy as shown
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in figure 8. The total height of the phantom is 89 mm, the mid-myocardial
diameter of the spherical and the cylindrical part 55 mm. The center of the
spherical part is located in the separation plane between the spherical and
the cylindrical part.
B
Left Ventricle
Right Ventricle
A
A
B
Long Axis
Mitral Valve Plane
LV Wall
z ’− axis
x ’− axis
y ’− axis
Figure 8: Anatomy of the heart and definition of the x’- and y’-axis [55].
The cylindrical part is divided into base and media, the spherical part
represents the apex. In order to obtain more located information these 3 main
parts are further subdivided in 4 VOIs (Volume Of Interest) each. Since the
septal and inferior part of base and media represent clinically differentiable
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Nr. name shortcut Nr. name shortcut
1 septal apex Sep - A 9 inferior media Inf - M
2 anterior apex Ant - A 10 posterior media Pos - M
3 lateral apex Lat - A 11 post. septal base Sepp - B
4 septal apex Inf - A 12 ant. septal base Sepa - B
5 post. septal media Sepp - M 13 anterior base Ant - B
6 ant. septal media Seppa - M 14 lateral base Lat - B
7 anterior media Ant - M 15 inferior base Inf - B
8 lateral media Lat - M 16 posterior base Pos - B
Table 2: Heart VOIs
areas, they are subdivided into two parts. The 16 different VOIs are listed
in table 2.
Figure 9: Segmentation of the LV and its x’ and y’ axis definition.
Image size (128x128x47), pixel size (2.24 mm in x- and y-direction, 3.38
mm in z-direction), and time schedule (table 3) were adjusted to the standard
protocol of cardiac PET-investigations in our department.
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4.2.2 Activity Levels of the Software-Phantom
The software phantom has been classified in 3 different types: inner
left-ventricular volume as a blood compartment, myocardial tissue and non-
myocardial tissue denominated as background.
Frame start length Frame start length frame start length
Nr. /s /s Nr. /s /s Nr. /s /s
1 0 30 14 150 10 26 630 60
2 30 10 15 170 20 27 780 150
3 40 10 16 190 20 28 930 150
4 50 10 17 210 30 29 1080 150
5 60 10 18 240 30 30 1230 150
6 70 10 19 270 30 31 1380 150
7 80 10 20 300 30 32 1530 150
8 90 10 21 330 60 33 1680 150
9 100 10 22 390 60 34 1830 300
10 110 10 23 450 60 35 2130 300
11 120 10 24 510 60 36 2430 300
12 130 10 25 570 60 37 2730 300
13 140 10
Table 3: Time schedule of a clinical FDG scan. (Injection in frame 2)
For the purposes of this work activity concentration has been calculated
using a numerical backward simulation of the FDG 3K-model described in
equation (5). As input curve a medium blood curve of the 10 patients was set.
The average was extracted by calculating the arithmetic mean after shifting
the peaks of image-derived input curves over each other. Finally, according
to the compartmental model, activity levels in the phantom myocardium
can be calculated by knowledge of the plasma activity concentration and the
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constants k∗1- k
∗
3 using equation (5).
4.2.3 Filtering and Background
Spatial resolution of a PET-scanner is limited; the exactly defined shape
of the phantom was smoothed using a Gauss-Filter of the order of 7 with
7.5 mm Full Width at Half Maximum (FWHM). Cardiac motion implies a
volume change of the heart of about 70-80 ml. Assuming an isotropic change
in volume this corresponds to a radius change of 5 mm which is simulated
by additional Gaussian filtering with 5 mm FWHM. A background of 10 to
20 % were added to software phantom activity levels.
4.3 Patient Data
Data from a patient with coronary artery disease was used to evaluate the
influences of motion on the absolute metabolic rate in different segments of
the heart. The database for the evaluation of artificial motion contains 5
patients with an infarct and 5 patients with hibernating myocardium. These
patients had been investigated in the years 1999 to 2001 in our department.
This group will be referred to further on as Patients with Artificial Motion
(PAM).
Data of 64 patients being investigated by means of PET between 1999
and 2001 for various cardiac diseases were analyzed and corrected for patient
motion. This group will be referred to as Patients with Clinical Motion
(PCM).
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4.4 Simulation of Motion
Motion is difficult to evaluate in clinical data because the absolute amount
of movement is not known. Hence artificial movement had to be forced and
evaluated.
4.4.1 Separation of Translation and Rotation
Disregarding warping effects motion of a patient can be described mathe-
matically as a rigid body transformation. As being a superposition of a
translation and a rotation these two types of movement can be separated as
visualised in figure 10.
φ
φ
s
y’−axis
P
z’−axis
z−axis
x−axis
Figure 10: Visualisation of correlation between translation and rotation. The
centre of rotation is P in the scanner coordinate-system, ~s the translational part
of movement and the rotation angle φ. The rotation is visualised by the dotted
line.
Every rotated dataset D′rot in heart coordinates x’, y’, and z’ (see figures
9 and 8) can be expressed by the product of the matrix M ′rot describing the
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rotation multiplied with the unrotated dataset in the heart coordinates D′.
The rotated dataset in scanner coordinate-system (x, y, z) D can be easily
achieved when applying the inverse transformation matrix T−1between the
two coordinate systems:
D′ = T · D,
D′rot = M
′
rot · D
′, (8)
Drot = T
−1D′rot = T
−1M ′rot · D
′.
4.4.2 Simulation of Translation
The simulation of movement was performed separately for different direc-
tions. Phantom data and original image data (not reorientated, PAM group)
obtained with a PET-scanner has been shifted in steps of whole pixel; shifts
were simulated for the three dimensions x, y, and z describing the geometry
of the PET-scanner as marked in figure 11.
4.4.3 Simulation of Rotation
Data of the software phantom and from the PAM group described in chapter
4.3 was reorientated an then rotated around the x’-, y’- and z’- axis describing
the intrinsic coordinate system of the heart (see figures 9 and 8) by means of
a trilinear interpolation algorithm.
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y
z
x
Figure 11: Definition of the x-, y-, and z-axis
4.5 PET-Scanner and Image Reconstruction
PET-Scans were performed on an ECAT Exact 921/47 (CTI, Knoxville; TN.)
registering 47 planes from 24 (24 real planes and 23 interpolated) detector
planes in a 15.4 cm field of view [63]. The scanner was run in 2D-mode
with tungsten septa between each detector plane. Before emission, transmis-
sion scanning was performed by 3 rotating 68Ge-line sources emission for 10
minutes. Emission data was collected according to the departmental time
schedule also used for the software phantom (table 3).
Emission data was corrected for attenuation and detector efficiency and
sorted in sinograms. For all purposes where the Patlak-Model was used re-
construction by filtered-back-projection with a cut-off at Nyquist frequency
was performed. Images used for registration was reconstructed using a iter-
ative OSEM method with 6 iterations and 16 subsets. Both methods were
performed at a zoom-factor of 2.3. Pixel size in reconstructed images was
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2.24 mm in x- and y-direction,and 3.38 mm in z-direction.
4.6 Quantitative Analysis of Glucose Metabolism
Patients (PAM and PCM) were investigated under the conditions of an eu-
glycemic clamp [13, 32]. The time schedule used for the acquisition was the
same as the one used for the design of the software phantom (chapter 3).
Images were reorientated, time activity curves of the blood where deter-
mined by drawing a VOI in the atrium of the left ventricle for the patient
data and in the center of the left ventricle for the phantom data, corrected
with late arterial samples [10]. For the software phantom, blood-sample data
was extracted from the average blood curve (see chapter 4.2.2).
The unbiased dataset of the myocardium was divided in 16 VOIs using
the last 3 frames. All datasets were reorientated exactly as the original
(unshifted or uncorrected) datasets. Those VOIs were applied to the shifted
or uncorrected datasets. All metabolic rates were calculated using the Patlak
model (chapter 2.2.4). The Lumped Constant LC in equation 3 was assumed
to be 1.
4.6.1 Clinical Processing
A general scheme for the classification of myocardial regions into clinically
relevant groups is presented in table 4. Performing this on simulated data,
each dataset is treated individually since a motion-biased dataset would be
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classified clinically in between itself.
diagnosis rel. glucose metabolism name
scar 0 - 50 % low
reduced metabolism 50 - 70 % medium
normal 70 - 100 % high
Table 4: Classification of the relative glucose consumption measured with FDG-
PET in clinically relevant groups [35]. Values are presented as relative numbers in
relation to the region with the maximum glucose metabolism.
The activity level of every region is calculated relatively to the region
with maximal glucose metabolism. Effects of motion in this work are evalu-
ated with a clinical scope by looking at the number of VOIs changing their
classification (VCC) and expressed in %.
4.7 Software Issues
Image reconstruction was carried out on a SUN workstation using the
ECAT 7.1 software (CTI Knoxville, TN, USA). All other data analysis was
performed on standard PCs using the mathematical software package MAT-
LAB 6 (The Mathworks Inc., MA, USA).
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5 Results
5.1 Clinical Relevance: Registration of Patient Motion
Figure 12 visualizes exemplary the operation of the SAD-algorithm in a one-
dimensional mode. Since the algorithm calculates principally the difference
between the two images, the SAD-value decreases, when the lower image is
shifted in the direction of the negative x-axis. Reaching the value of best
agreement (lowest difference of the two images) the SAD-value reaches a
minimum. For the purposes of this work this algorithm was conducted in a
full three-dimensional mode.
Motion registration was performed on iterative reconstructed images since
it worked more reliable than on images reconstructed by the filtered back-
projection. 63 datasets were investigated (PCM group), motion registrated
by the algorithm was recognized as patient motion when being in a range
of more than one pixel. The distribution of shifts is shown in figure 13
whereas patient movement did appear often not only within one frame but
was distributed over some frames.
5.2 Validation I: Simulation vs. Artificial Motion
5.2.1 Software Phantom
Patient data of 10 patients was chosen to derive k∗1- k
∗
3 (nominated as k
∗
i -)
for the software phantom. This simulation-process is sometimes numerically
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Figure 12: Operation of the registration algorithm: the regions depicted in both
images are located identically.
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Figure 13: Results of the registration algorithm
bad-conditioned: of 160 calculated regions and their k∗i -values those with
convergence and an acceptable error rate were used. Three phantom k∗i -sets
(16 per phantom) were randomly chosen. Only their distribution over the
classification ranges (see chapter 4.6.1) was prescribed to be similar to those
of the patient data.
5.2.2 Translation of Phantom and Patient Data
Patient motion (PAM group) at times of 45 minutes and shifts of 10 pixels
could not be simulated for every patient, since the numerical algorithm failed.
10 patients were investigated so that 320 regions were investigated for each
data point. Translation was simulated from -10 to 10 pixels in steps of 2 for
each dimension, resulting in shifts in the x- and y-direction of -22 mm to 22
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mm in steps of 4.5 mm and -34 to 34 mm in steps of 6.8 mm in z-direction.
Typical effects on Patlak-evaluations are shown in figure 14.
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Figure 14: Effects of translation on Patlak-plot for a translation of 8 pixels in
x-direction, region Inf-B: left before frame 30 (20.5 min.), right before frame 37
(40.5 min)
Starting with the anatomical phantom simulated data systematical over-
estimated motion effects retrieved from patient data. It was determined
empirically, that next to the background level myocardial thickness is a key
parameter in this simulation. Analyzing patient data, the assumption of a
12.5 mm myocardial thickness did not match clinical results of the group
of 10 patients (PAM group), examples for different myocardial shapes can
be found in figure 15. Selected patients of the group showed similar influ-
ences of shifts like the 12.5 mm-phantom, more precisely those with a thin
myocardium. Since the myocardial thickness of a patient is impossible to
characterize with a single number visual inspection was carried out. In con-
trast to the anatomical approach of figure 7 the data represented here has
a myocardial thickness of 20 mm and represents the mean thickness of the
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patient database more precisely.
0
1
2
3
4
5
/ 104 Bq /cm3
0 10 20 30
/ pixel
0
0,2
0,4
0,6
0,8
1
re
la
tiv
e 
ac
tiv
ity
 c
on
ce
nt
ra
tio
n 
Pat. 1
Pat. 2
Phantom 1
Phantom 2
Figure 15: Effects of myocardial thickness on the line profiles of the myocardial
wall (left). Comparison of the marked line profile of a thick myocardium (patient
1) with a thin myocardium (patient 2) and 2 phantoms representing different
myocardial thicknesses and background levels. Colorbar values are relative.
Since 3 phantoms with 16 regions each were investigated in this figure
and shifts in the positive and negative direction were summed, 96 regions
were investigated.
5.2.3 Rotation of Phantom and Patient Data
Figure 17 shows data from rotation simulations. Phantom data is represented
from rotations of 4◦ to 19◦ compared with one 16◦ rotated datasets of the
patient group.
5 RESULTS 47
patient data phantom data
0 10 20 30 40 50
time of movement / min.
0
10
20
30
40
VO
Is
 c
ha
ng
in
g 
th
ei
r c
la
ss
ific
at
io
n 
/ %
10 pixel
  8 pixel
  6 pixel
  4 pixel
  2 pixel
0 10 20 30 40 50
time of movement / min
0
10
20
30
40
VO
Is
 c
ha
ng
in
g 
th
ei
r c
la
ss
ific
at
io
n 
/ %
10 pixel
  8 pixel
  6 pixel
  4 pixel
  2 pixel
0 10 20 30 40 50
time of movement / min.
0
10
20
30
40
VO
Is
 c
ha
ng
in
g 
th
ei
r c
la
ss
ific
at
io
n 
/ %
10 pixel
  8 pixel
  6 pixel
  4 pixel
  2 pixel
0 10 20 30 40 50
time of movement / min.
0
10
20
30
40
VO
Is
 c
ha
ng
in
g 
th
ei
r c
la
ss
ific
at
io
n 
 / 
%
10 pixel
  8 pixel
  6 pixel
  4 pixel
  2 pixel
0 10 20 30 40 50
time of movement / min.
0
10
20
30
40
VO
Is
 c
ha
ng
in
g 
th
ei
r c
la
ss
ific
at
io
n 
/ %
10 pixel
  8 pixel
  6 pixel
  4 pixel
  2 pixel
0 10 20 30 40 50
time of movement / min.
0
10
20
30
40
50
VO
Is
 c
ha
ng
in
g 
th
ei
r c
la
ss
ific
at
io
n 
/ %
10 pixel
  8 pixel
  6 pixel
  4 pixel
  2 pixel
Figure 16: Effects of translation: x- (1. row), y- (2. row), and z-direction (3.
row), all translations noted with their absolute value in the positive direction: left
patient data, right phantom data
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Figure 17: Effects of rotations around different axis: x’- and y’- (average left),
and z-direction (right), all rotations noted with their absolute value in the positive
direction: left patient data, right phantom data
5.3 Validation II: Simulation vs. Clinical Motion
Effects of motion on the classification of glucose metabolism on artificial
moved data was compared to those in clinical data: movement in clinical
data was registrated and corrected and effects on classification evaluated.
Those effects were compared to effects on artifical moved datasets of the same
absolute value, same main direction and same time point during acquisition
(figure 18). Error bars in figure 18 for patient (PAM group) and phantom
data are derived from the estimation of the time of movement: it could not be
assigned to one point since most patients did not show a sudden movement
but a distribution over adjacent planes. Error bars for the patient data (PCM
group) are correlated to the sampling interval: one frame of 16 is related to
be 6.25 % of the frames.
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Figure 18: Effects of motion correction on classification of myocardial regions:
ratio of corrected vs uncorrected patient data (PCM group) compared to artificial
shifted patient (PAM group) and phantom data.
6 Discussion
6.1 Clinical Relevance: Motion Detection
Motion was clearly detected in 24 ( = 38 %) patients (PCM group, figure
13). This incidence fulfilled the expectations, that due to longer acquisition
times and better resolution of PET-systems motion is visible more frequently
than in SPECT-acquisitions ( 17 - 25 % for cardiac 201Tl-investigations [51,
5, 21, 20]). The rate of 38 % can be treated as lower limitation, since shifts
up to 5 mm were assumed to be zero and the registration method operated
only in counts of whole pixels. This result is supported by a PET study,
where serious effects of motion on absolute quantified blood flow by means of
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13N-ammonia were achieved [41] but no rate of motion occurence was given.
The disadvantage of losing resolution in the registration process is com-
pensated by leaving pixel-values in the original sampling and excluding bias-
ing by resampling [1] which is important in this quantitative study.
6.2 Validation I: Simulation vs. Artificial Motion
6.2.1 Translation
General effects in figure 16 are similar for all directions and both simula-
tions: motion effects increases with the amount of shift and contributes to
the effects, only when occurring at least 5 min. after injection. Effects gain a
local maximum and decrease at times up to 40 min to increase at later times.
A kind of linearity with the amount of motion appears for motion up to 6
pixel, whereas larger shifts do not increase the VCC substantially, especially
in phantom data.
The general trend can be explained, when considering a VOI falsely po-
sitioned due to patient motion is shifted to its right position after the time
of movement. The right placement of a VOI inherits an increase of the value
for the concentration of FDG in tissue c∗i (t) by a relative factor (see figure
14). Two effects are superpositioned:
1. The later the motion occurs, the fewer points lie on the right position
and the higher is the effect: the slope is underestimated (see figure 14,
right).
6 DISCUSSION 51
2. When assuming that the plasma concentration c∗p(t) being unbiased,
the combined slope of the biased and unbiased part of the tissue con-
centration c∗i (t) is calculated. The slope is overestimated when patient
motion occurs in the middle of the acquisition (see figure 14, left).
In patient motion events at acquisition times of 35 to 40 minutes both effects
cancel out each other to a certain extent, resulting in the local minimum
visible in patient and phantom data.
Saturation for large shift values effects can be explained by finding the
VOI far outside the myocardium: shifting a software phantom with 200 mm
myocardial thickness 8 pixels in (y, y-direction: 19.2 mm; z-direction: 25.6
mm) perpendicular to the epicardium, the VOI is placed outside the my-
ocardium (nearly) in its whole. Shifting the VOI further 2 pixels at a constant
input curve worsens the effect for the well defined phantom data only slightly.
Patient data is more inhomogeneous: changes in VOI activity-concentrations
can also occur far outside the VOI’s original position so that motion effects
are still visible.
The shape of a line profile of the myocardium seems to be a key parameter
in software phantom simulation; the differences in shape are shown in figure
15. Comparing 3 patients with a thin myocardium selected from the PAM-
group with the simulation of a phantom of 12.5 mm myocardial thickness
similar results were achieved. These is explained easily when comparing at
a fixed amount of shift the ratio between the correctly placed part of a VOI
and the misaligned part relative to the myocardium. The ratio is higher
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for a thin myocardium and can bias the VOI’s activity-concentrations and
hence glucose metabolism calculation more seriously. It can be concluded
that motion effects depend strongly on the single dataset.
The comparison of patient group (PAM group) and phantom data reaches
a limit at a certain amount of movement. One systematical reason additional
to the saturation effect can be found in the different types of input curves
used: input curves were generally achieved by placing VOIs in a blood pool
region, atrium for patients and left ventricle for phantom data. Patient data
was extracted from biased datasets whereby those for phantom data was
taken as constant, like being derived with a blood sampling device [4, 62].
For the ranges of motions detected (up to 6 pixel) in clinical data both
approaches did not show significant differences. The blood pool region of
patient motion biased data will be shifted into the myocardium at higher
shift levels and will affect the result of Patlak analysis more than a constant
input curve. Furthermore, neighbouring organs (e.g. liver) might be stripped
by the blood regions.
6.2.2 Rotation
Rotation was investigated in an artificial coordinate system which does not
reflect common rotations of patient movement. The amount of translation
from a rotational movement depends strongly on the distance between ro-
tation centre and the left ventricle (see figure 10). Rotation centres can be
assumed to be different from patient to patient. Independency of the effects
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of rotational movement from the distance of rotation centre and left ventricle
is achieved by the used coordinate system.
Rotations in this orientation have, generally spoken, smaller effects on the
VCC than translations, particular rotations around the z’-axis. Behaviour
of effects with time are similar to those observed with translational patient
motion. Saturation effects are not observed. Comparison to patient data
shows similar trends.
The lack of saturation can be explained since a rotational movement of a
small amount will not displace a VOI totally from its correct placement: a
further rotation will continously lead to further effects.
As the geometry of the left ventricle suggests, the rotational part of pa-
tient movement (seperated from a global patient movement according equa-
tion 8) does not affect the values for glucose metabolism seriously. The
range of rotations presented seems to be quite high: simulated 2 h brain
studies from 30 patients [45] showed rotations (sagittal plane: 0◦-14◦ (mean
2.8◦), transaxial plane: 1.5◦-21◦ (mean 4.9◦), coronal 0◦) whereby only the
behaviour of coronal plane might be compared with the constrained situa-
tion of the heart during a PET-acquisition. A rotation of 2◦ corresponds
to approximately a 1 mm shift in a myocardium with the geometry of the
presented phantom. Comparing rotational effects to those from translational
movement they might be disregarded and the correction of patient movement
only for the translational amount is justified.
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6.3 Validation II: Simulation vs. Clinical Motion
Comparison of the effects of motion-correction on the absolute quantification
showed similar results. The differences between patient-simulation (PAM
group) and phantom-simulation are consistent with the relative differences
in figure 18. Some discrepancies occurred especially in the two patients with
large effects on the VCC. This is consistent with the conclusion, that motion
effects depend strongly on the single dataset as reported in [41]. A prediction
of the effect of patient motion on a single dataset is not possible: neither
the comparison with the artificial moved patient data nor with the artificial
moved software phantom would match firmly the single circumstances. In
this comparison, software phantom data competes with artificially moved
patient data (PAM group).
6.4 Limitations
The software phantom implies an idealisation of the anatomy and physiology
of the heart. Results from the software phantom data cannot be transferred
to clinical data without restrictions as explained above. Some reasons for the
limitations of the presented approach and patient data are to be mentioned
here:
• The activity level of each of the 16 heart regions can be set individually.
In a human heart neighbouring regions are not as independent and the
metabolic states do not differ like in phantom data. Shifting similar
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regions into each other might cause lower effects
• The occurence of patient motion in phantom data was assumed to be
sudden. On the other hand patient data often included motion oc-
curence distributed over a few frames.
• Phantom data has a well-defined geometry with respect to myocar-
dial thickness whereas patient data shows intra subject variations (e.g.
papillary muscles).
• The orientation of the phantom heart is assumed to be 45◦ proned
in each direction (x, y, z). Variations to these orientation might be
found in reality. Inhomogeneity in different directions might be partly
explained by this fact.
• The phantom heart is a quite symmetric body. Hence, especially for
rotations around the z’-axis underestimated results occur.
• Transmissions scans were performed before the dynamic emission scans.
This had no effect on the simulated movements, as motion was per-
formed after transmission correction of the datasets. Motion correction
of patient data was only applied to reconstructed datasets, where a
misalignment between emission and transmission was present. Effects
of discrepancies in correct alignment are known [52, 39].
• The motion registration approach used in this work is no “high-end”-
procedure but a fast algorithm. It might not obtain the best achievable
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results for motion registration. A review of state-of-the-art methods
can be found in [28].
• Normally regions are drawn in the frames of a study, where anatomy
is most visible; although a check for the right alignment of the regions
might reduce the errors: if patient motion occurs the investigator might
place the regions in the middle of these two regions, select smaller or
wider regions, all biasing the result. If motion occurs in the last frames
rejection of these would be a solution without motion correction.
• The movements in different directions and of different types might not
be distributed similarly because the geometric limitations of patient
movement due to the small aperture of a PET-scanner.
Taking these sources of errors into account, the presented results of the soft-
ware phantom and the clinical datasets match each other in a satisfactory
manner.
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7 Conclusion
It has been shown that patient motion is a serious challenge in quanti-
tative cardiac PET. It was determined that patient motion occurs in more
than a third of the patients, a dedicated work on motion registration might
detect even higher rates.
Influences of patient motion simulated in detail on a new developed fully
dynamic cardiac software phantom could be applied to real data. No quan-
titative perfect match was achieved since simulation effects are strongly de-
pendant of the geometry of the single patient or phantom myocardium. Nev-
ertheless, general influences could be determined precisely. The model seems
to be applicable to the investigation of various kinds of spatial influences
(cardiac gating, respiratory gating) in quantitative cardiac PET.
Hybrid systems will not solve the discussed intra study motion problem
in dynamic acquisitions since the acquisition of physiological data with PET
and anatomical data is conducted separately and the static anatomical data
set, that does not include any information about the patient motion.
Again the basic need for a reliable motion correction algorithm in the
clinical routine was demonstrated.
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